EconomyLens.com
No Result
View All Result
Tuesday, June 17, 2025
  • Home
  • Economy
  • Business
  • Markets
  • Tech
  • Editorials
EconomyLens.com
  • Home
  • Economy
  • Business
  • Markets
  • Tech
  • Editorials
No Result
View All Result
EconomyLens.com
No Result
View All Result
Home Economy

Biden calls for lower prices of Ozempic, similar drugs

Thomas Barnes by Thomas Barnes
July 2, 2024
in Economy
Reading Time: 5 mins read
A A
0
41
SHARES
507
VIEWS
Share on FacebookShare on Twitter

US President Joe Biden and Senator Bernie Sanders accused pharma firms Novo Nordisk and Eli Lilly of "price gouging". ©AFP

Washington (AFP) – US President Joe Biden on Tuesday called on pharmaceutical giants Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs such as Ozempic, saying firms must stop “ripping off the American people.”

Related

Trump says EU not offering ‘fair deal’ on trade

UK automakers cheer US trade deal, as steel tariffs left in limbo

Global oil demand to dip in 2030, first drop since Covid: IEA

US retail sales slip more than expected after rush to beat tariffs

Why stablecoins are gaining popularity

In an article written with Senator Bernie Sanders, Biden said US patients pay several times more than those in Canada, Germany and Denmark for Novo Nordisk’s diabetes drugs Ozempic and Wegovy, which can also be used for weight loss. A one-month supply of Ozempic in the United States last year was $936, compared to $169 in Canada and $103 in Germany, according to one study.

Eli Lilly was also charging “unconscionably high prices” for Mounjaro, a drug similar to Ozempic. “Why should people in Burlington, Vermont, pay so much more than people in Copenhagen or Berlin for the same drug?” wrote Biden and Sanders, who chairs the Senate committee on health and education.

Such “price gouging” makes the drugs unaffordable to millions of Americans, they said. “If the prices of these drugs are not substantially reduced, they have the potential to bankrupt the American health care system,” Biden and Sanders wrote. “We will not allow that to happen.”

In a statement to AFP, Novo Nordisk said it takes “patient access and affordability very seriously,” adding it was “disappointed that a very difficult and complex problem is being oversimplified and mischaracterized for political purposes.” The cost of Ozempic and Wegovy has decreased approximately 40 percent since their launch, it added, while admitting: “Even when we lower our prices, patients in the United States often don’t receive the savings — this is a problem.”

Eli Lilly said it offers Mounjaro, marketed to diabetes patients, and Zepbound, sold as a weight loss drug, “for as low as $25 a month to those eligible for our savings card program.” “Comparing list prices in the United States to other countries ignores patient affordability programs and hundreds of billions of dollars in discounts and fees” paid to intermediaries by pharmaceutical companies “that should lower the costs of medicines for Americans, but unfortunately this system can drive prices higher,” Eli Lilly said in a statement to AFP.

High prices for prescription drugs have been a long-standing problem for American patients, and Biden has focused on lowering health care costs as part of his campaign for reelection in November. The piece in USA Today comes days after Biden’s weak performance during a televised presidential debate with Republican Donald Trump sparked sharp concern among Democrats.

© 2024 AFP

Tags: drug priceshealthcarepharmaceuticals
Share16Tweet10Share3Pin4Send
Previous Post

Vote-ready UK waits to scoop up Brexit boost

Next Post

US stocks back at records while European bourses retreat

Thomas Barnes

Thomas Barnes

Related Posts

Economy

Bank of Japan holds rates, will slow bond purchase taper

June 17, 2025
Economy

Ecuador pipeline burst stops flow of crude

June 16, 2025
Economy

Yen slides ahead of Bank of Japan policy decision

June 16, 2025
Economy

War, trade and Air India crash cast cloud over Paris Air Show

June 16, 2025
Economy

China factory output slows but consumption offers bright spot

June 16, 2025
Economy

US Fed set to hold rates steady in the face of Trump pressure

June 16, 2025
Next Post

US stocks back at records while European bourses retreat

Athens Acropolis introduces private visits for 5,000 euros

Amazon counts on 'grit and innovation' to meet AI surge

Markets track Wall St records as Powell revives rate hopes

0 0 votes
Article Rating
Subscribe
Notify of
guest
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
  • Trending
  • Comments
  • Latest

New York ruling deals Trump business a major blow

September 30, 2024

Elon Musk’s X fights Australian watchdog over church stabbing posts

April 21, 2024

Women journalists bear the brunt of cyberbullying

April 22, 2024

France probes TotalEnergies over 2021 Mozambique attack

May 6, 2024

Ghanaian finance ministry warns against fallout from anti-LGBTQ law

74

New York ruling deals Trump business a major blow

72

Shady bleaching jabs fuel health fears, scams in W. Africa

71

Stock markets waver, oil prices edge up

65

US retail sales slip more than expected after rush to beat tariffs

June 17, 2025

Taiwan tests sea drones as China keeps up military pressure

June 17, 2025

G7 leaders urge Trump to ease off trade war

June 17, 2025

Oil prices rally, stocks slide as traders track Israel-Iran crisis

June 17, 2025
EconomyLens Logo

We bring the world economy to you. Get the latest news and insights on the global economy, from trade and finance to technology and innovation.

Pages

  • Home
  • About Us
  • Privacy Policy
  • Contact Us

Categories

  • Business
  • Economy
  • Markets
  • Tech
  • Editorials

Network

  • Coolinarco.com
  • CasualSelf.com
  • Fit.CasualSelf.com
  • Sport.CasualSelf.com
  • SportBeep.com
  • MachinaSphere.com
  • MagnifyPost.com
  • TodayAiNews.com
  • VideosArena.com
© 2025 EconomyLens.com - Top economic news from around the world.
No Result
View All Result
  • Home
  • Economy
  • Business
  • Markets
  • Tech
  • Editorials

© 2024 EconomyLens.com - Top economic news from around the world.